Biotechnology News

Biotechnology News – including medical research, studies, human genome, bio-technology devices and services news, as issued by the Send2Press Newswire service.


Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay for Early Detection of Tissue Injury and Prevention of Organ Rejection

AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.

Neurotech Reports Announces Launch of New Publication Serving Bioelectronic Medicine Industry

SAN FRANCISCO, Calif., Nov. 8, 2021 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.

Kalyagen™ Announces Registration of STEMREGEN%C2%AE in Spain, CEO at Madrid Stem Cell Symposium

AUSTIN, Texas, Oct. 12, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau’s, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors

ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company’s board of directors.

KROST Acts as Exclusive Financial Advisor for Integrity Bio in Sale to Curia

LOS ANGELES, Calif., Aug. 11, 2021 (SEND2PRESS NEWSWIRE) — Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

AUSTIN, Texas and CAMBRIDGE, U.K., July 21, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke’s Hospital.

BioAustin Appoints New Leadership and Unveils An Expanded Strategic Focus In Central Texas As BioAustinCTX

AUSTIN, Texas, June 3, 2021 (SEND2PRESS NEWSWIRE) — Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas, March 31, 2021 (SEND2PRESS NEWSWIRE) — Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas and LOOS, France, March 24, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC).

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

AUSTIN, Texas and EVANSTON, Ill., March 17, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) — Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

AUSTIN, Texas and BIRMINGHAM, Ala., March 11, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease

AUSTIN, Texas and LONDON, England, Feb. 24, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King’s College London.

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) — Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb. 9, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 4, 2021 (SEND2PRESS NEWSWIRE) — Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

AUSTIN, Texas and BASEL, Switzerland, Jan. 27, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.

Microcide Announces Launch of Speed-breaker for Fast Moving COVID-19 Infections for Health Care Facilities

STERLING HEIGHTS, Mich., Jan. 4, 2021 (SEND2PRESS NEWSWIRE) — Microcide® Inc. a leading Michigan based biotechnology company, today announced the test results of its COVID-19 faster virus killing range of products, PRO-SAN® Cleaner sanitizer, SILKY-SOFT® hand sanitizer, and DENTORAL® mouthwash.

Synthetic Biology for Tennessee Schools: BioBuilder Partners with Niswonger Foundation on $8.8M Federal Grant for STEM Education

CAMBRIDGE, Mass., Dec. 29, 2020 (SEND2PRESS NEWSWIRE) — The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an “Education Innovation and Research” (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM).

Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers

OKLAHOMA CITY, Okla. and AUSTIN, Texas, Nov. 30, 2020 (SEND2PRESS NEWSWIRE) — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website.

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va., Oct. 28, 2020 (SEND2PRESS NEWSWIRE) — Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif., Oct. 26, 2020 (SEND2PRESS NEWSWIRE) — The American College of Gastroenterology (ACG) named Progenabiome “Outstanding Poster Presenter” for its poster: “Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection,” which will be presented virtually at the ACG Annual Scientific Meeting this week.

Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting

OKLAHOMA CITY, Okla. and AUSTIN, Texas, Oct. 15, 2020 (SEND2PRESS NEWSWIRE) — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 – 21, 2020.

Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery

STONY BROOK, N.Y., July 20, 2020 (SEND2PRESS NEWSWIRE) — Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif., April 2, 2020 (SEND2PRESS NEWSWIRE) — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

Lyme Disease Biobank Expands Into San Diego

SAN DIEGO, Calif., March 6, 2020 (SEND2PRESS NEWSWIRE) — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation’s Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y., Nov. 14, 2019 (SEND2PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

Hans van der Sluijs Joins BioTork as Chief Development Officer

GAINESVILLE, Fla., Oct. 30, 2019 (SEND2PRESS NEWSWIRE) — BioTork, the leading evolution biotechnology company, today announced that biotech executive Hans van der Sluijs has joined the company as Chief Development Officer. Hans brings over 20 years of international business leadership experience, with a focus on business development, management, and building strategic alliances/partnerships.

Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif., Oct. 8, 2019 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Brandon Stem Cell Clinic Offers Life-changing Treatment Options

TAMPA, Fla., Aug. 12, 2019 (SEND2PRESS NEWSWIRE) — Brandon Stem Cell Clinic (BSCC) recognizes that osteoarthritis is one of the most common joint conditions, affecting nearly 630 million people worldwide. It is commonly associated with aging but is also frequently seen in cases of overuse of joints. The growing number of cases alone prove a need for innovative and effective treatments as populations continue to age. (VIDEO)

New Market Research Report on Bioelectronic Medicine Forecasts $16.6B Market

SAN FRANCISCO, Calif., May 9, 2019 (SEND2PRESS NEWSWIRE) — A newly published market research report from Neurotech Reports, the leading market intelligence firm in the neurotechnology industry, forecasts that the worldwide market for bioelectronic medicine and related technologies will reach $16.6 billion by 2025.

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla., Feb. 21, 2019 (SEND2PRESS NEWSWIRE) — The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Sue Siegel to Keynote 2019 Bioelectronic Medicine Forum in NY

NEW YORK, N.Y., Feb. 20, 2019 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announces that Sue Siegel, Chief Innovation Officer at GE and CEO of GE Ventures, will keynote the 2019 Bioelectronic Medicine Forum, which takes place in New York City on April 4, 2019.

Neurotech Reports Announces 2018 Investment and Management Conference for Bioelectronic Medicine

NEW YORK, N.Y., Jan. 30, 2018 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Iron Dust from Brakes and Worldwide Magnesium Deficiencies are Contributing to Hypertension

KESWICK, Va., Nov. 14, 2017 (SEND2PRESS NEWSWIRE) — With 25 years of research involving primarily the cardiovascular complications of spaceflight and more recently of the moon walkers, particularly Neil Armstrong on his historic mission and James Irwin (Apollo 15), extraordinary findings were discovered. Both had vascular complications, triggered by inhalation of deadly iron-laden dust. Author Dr. William J. Rowe has applied this information as to how this can be utilized for underlying mechanisms of hypertension on earth, triggered by iron-laden brake dust.

ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection

SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

Medical Experts Unite Regarding Health Benefits of Testosterone Therapy in Women

IRVING, Texas, April 19, 2017 (SEND2PRESS NEWSWIRE) – BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

Solesence and Colorescience Announce Skin Care Collaboration

ROMEOVILLE, Ill., Jan. 31, 2017 (SEND2PRESS NEWSWIRE) — Solesence, a skin care product manufacturer at the forefront of environmental protection technology, has announced a partnership with leading prestige beauty brand Colorescience in a special collaboration to develop products for skin care and protection. As part of their joint development and supply relationship, Solesence will use patented mineral skin care actives technology to develop sunscreen products exclusively for Colorescience.